Extended-release amantadine may improve levodopa dyskinesia control
VANCOUVER – An extended-release amantadine formulation reduced levodopa-induced dyskinesia in a phase III Parkinson’s disease trial from the drug’s developer, Adamas Pharmaceuticals.
Amantadine...
Source: Family Practice News - Category: Primary Care Source Type: news
More News: Amantadine | Carbidopa/Levodopa | Dyskinesia | Family Practices | Primary Care | Symmetrel